Epizyme reports positive interim data By: MarketMinute.com Stock News June 14, 2017 at 18:27 PM EDT Epizyme Inc. (Nasdaq: EPZM) reported upbeat interim data from a Phase 2 clinical trial of tazemetostat. Shares of the biopharmaceutical climbed $1.20 to close at $12.35. Related Stocks: Epizyme Inc